Individuals with first-degree relatives affected by the condition are twice as likely as those in the general population to experienced gout.
Elevated uric acid levels are associated with increased risks for hypertension, gout, and renal impairment.
Patients with gout experienced no clinically significant urate-lowering effects from an 8-week course of a modest dosage of vitamin C.
Many but not all cohort studies examining the relationship between hyperuricemia and CKD outcomes suggest they may be intertwined.
Adverse events included skin rash, gastrointestinal problems, and allopurinol hypersensitivity syndrome.
Gout prevalence is higher among patients with lower average estimated glomerular filtration rates or higher levels of albuminuria
The two are linked regardless of gender, race, and obesity.
An consumption over a two-year period found to decrease likelihood of a gout attack by 35%.
Data from 5,707 participants of the National Health and Nutrition Examination Survey (NHANES) 2007-2008 show that gout now affects 4% of Americans (8.3 million individuals), and hyperuricemia, 21% (43.3 million).
A case study involving a 58-year-old man with acute gout attacks and multiple comorbidities, including hypertension and hypercholesterolemia.
A case study involving a 65-year-old man with chronic kidney disease and acute attacks of pain, swelling, and erythema in the first metatarsophalangeal joint.
Gout patients have an increased prevalence of simple renal cysts, and these cysts are associated with a decreased likelihood of kidney stone disease, according to Brazilian investigators.
A case study examines the treatment of hyperuricemia and gout in a 57-year-old postmenopausal renal transplant recipient with intermittent gout attacks.
Gout is increasingly recognized in patients with chronic kidney disease, but the proper dosing regimen for traditional agents has not been well-studied in this patient group.
PHILADELPHIA—Patients with chronic kidney disease (CKD) have a relatively high prevalence of gout compared with the general population, according to data presented at Kidney Week 2011.
CHICAGO—Uncontrolled serum uric acid in patients with gout is associated with an increased risk of developing kidney disease and diabetes, according to the findings of two studies presented at the American College of Rheumatology annual meeting.
VANCOUVER, B.C.—Allopurinol can be prescribed safely to treat recurrent gout in renal transplant recipients who are receiving azathioprine, British researchers reported.
The FDA has ordered a halt to the marketing of unapproved single-ingredient oral colchicine, a medication commonly used for the daily prevention of gout, to treat acute gout flare-ups, and for the treatment of familial Mediterranean fever.
Savient Pharmaceuticals, Inc., of East Brunswick, N.J., has received FDA clearance to market Krystexxa (pegloticase) as a treatment for chronic gout in adult patients refractory to conventional treatment.
MUNICH, GERMANY—Allopurinol, a drug long used to treat gout, can cause regression of left ventricular hypertrophy (LVH) and improvement of endothelial dysfunction in CKD patients, a study found.
Allopurinol, a drug used to treat gout, may slow progression of kidney disease in CKD patients, according to new findings scheduled to be published in an upcoming issue of the Clinical Journal of the American Society of Nephrology.
Colcrys, a new colchicine formulation, has received marketing clearance for the prevention of gout flares.
The FDA's Arthritis Drugs Advisory Committee has recommended that Krystexxa (pegloticase) be approved for treating refractory chronic gout.
A new oral medication that reduces serum uric acid levels has received FDA approval for treating hyperuricemia in patients with gout.
A short course of a corticosteroid could supplant nonsteroidal anti-inflammatory drugs (NSAIDs) as the medication of choice to treat gout, Dutch researchers suggest.